# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

> **NCT05513950** · PHASE1 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 52 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **BIOLOGICAL:** CHF10067 starting dose -- 1000mg (Cohort A)
- **BIOLOGICAL:** CHF10067 intermediate dose -- 2000mg (Cohort B)
- **BIOLOGICAL:** CHF10067 high dose -- 3000mg (Cohort C)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05513950
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-25
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-06-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05513950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05513950, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05513950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*